


## PPD ranked 2nd by CenterWatch CRO site survey

02 May 2013 | News | By BioSpectrum Bureau



**Singapore:** Pharmaceutical Product Development's (PPD) site has been acknowledged by CenterWatch's 2013 Global Investigative Site Relationship Survey for reputation among all contract research organizations (CROs). CenterWatch provides clinical trials information to a broad and influential spectrum of clinical research professionals

PPD is also ranked second on investigative sites' evaluation of their clinical trial relationships with CROs. Overall, PPD was ranked among the top three CROs on all 36 relationship attributes that the questionnaire asked of clinical research professionals at investigative sites globally.

PPD has also been ranked best in "being an innovator in finding ways to improve its relationships with sites and using technology to make processes more efficient, [using] data analytics to help target where sites might have a potential issue," according to *CenterWatch Monthly*, which published the survey results. "PPD uses its analytics to improve productivity and quality across all project functions, not just monitoring," the publication said.

Clinical research professionals at 2,032 global sites completed the biennial survey, the largest CenterWatch has conducted until now in order to measure the quality of working relationships between CROs and sites conducting clinical research.

Mr Paul Colvin, executive vice president, global clinical development, PPD, said that, "We work to hire, train and retain the best team in the industry. We feel that trust, accountability, performance and results are the basis of PPD's strong reputation within the industry and the foundation of our relationships with our biopharmaceutical clients and our investigative sites. Investigative sites are critical partners in clinical research. And strong site relationships are vital to our efforts to bend the cost

and time curve of drug discovery and development to help our clients deliver life-changing medical therapies to the market faster, more cost effectively and with the highest possible quality."